Benitec Biopharma Limited (NASDAQ:BNTC) Receives Consensus Recommendation of "Moderate Buy" from Analysts
Market Beat·
- Benitec Biopharma Limited has received a consensus recommendation of "Moderate Buy" from ten covering brokerages, with a 1 - year average price target of $24.80.
- The company's stock opened at $13.48 with a market capitalization of $463.04 million, while institutional investors and hedge funds currently own 52.19% of the shares.
- Benitec Biopharma is a clinical-stage biotechnology company that develops gene-silencing therapies utilizing its proprietary DNA-directed RNA interference platform.